{
  "docId": "019de076-567f-77cd-b2fe-46fe5b90ebce",
  "docSlug": "f071473f2318bf29da28de95df17ba43",
  "documentTitle": "Matinas BioPharma | Investor Presentation Deck | 31 slides",
  "authorId": "matinas-biopharma",
  "authorName": "Matinas BioPharma",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 29,
  "pageCount": 31,
  "prevPage": 28,
  "nextPage": 30,
  "slideType": "unfair_advantage",
  "function": "present_solution",
  "density": "dense",
  "nDataPoints": 3,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-567f-77cd-b2fe-46fe5b90ebce/29",
  "deckHref": "/decks/019de076-567f-77cd-b2fe-46fe5b90ebce",
  "deckJsonHref": "/decks/019de076-567f-77cd-b2fe-46fe5b90ebce.json",
  "deckAnchorHref": "/decks/019de076-567f-77cd-b2fe-46fe5b90ebce#slide-29",
  "components": [
    {
      "bbox": {
        "h": 0.12,
        "w": 1,
        "x": 0,
        "y": 0.78
      },
      "kind": "callout",
      "text": "Strong IP & Regulatory Designations",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c8a20d7e-0c4b-43c3-9955-4101da6e7398",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.73,
        "x": 0.135,
        "y": 0.285
      },
      "kind": "image",
      "text": null,
      "attrs": null,
      "subkind": "icon-grid",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8fd34853-1790-4097-96ac-1db232ec45d4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.25,
        "x": 0.64,
        "y": 0.515
      },
      "kind": "list",
      "text": "Recent patent applications based on formulation work with small oligonucleotides",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0c15c950-c95c-4d6d-8887-1e7dbdefe1ae",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.25,
        "x": 0.11,
        "y": 0.515
      },
      "kind": "list",
      "text": "MAT2203 potentially entitled to 12+ years of exclusivity (QIDP & Orphan status)",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "11958ffb-8957-4755-9507-0ae8442f9045",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.25,
        "x": 0.375,
        "y": 0.515
      },
      "kind": "list",
      "text": "Global Platform IP base protection out to 2037 with 20 patents issued in last 5 years",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d115b890-e1d3-4bb3-adf4-bd4b3722b813",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.035,
        "w": 0.72,
        "x": 0.14,
        "y": 0.205
      },
      "kind": "title",
      "text": "Continuing increasing our patent suite to increase protection and exclusivity",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5dc39175-c359-42f7-9a69-bd424f126976",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.035,
        "w": 0.43,
        "x": 0.048,
        "y": 0.078
      },
      "kind": "title",
      "text": "Expanding LNC Intellectual Property Portfolio",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4ada2b75-513d-431e-907d-bd4208e73b1d",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Audience Definition",
      "slug": "audience-definition",
      "agent": "Storyteller",
      "layer": "slide",
      "matchId": "a5ef9fd3-4b93-443b-947e-0af563bd847a",
      "evidence": "The slide appears to be focused on the company's intellectual property portfolio, suggesting that the audience is interested in understanding the company's assets and competitive advantage.",
      "confidence": 0.7
    },
    {
      "name": "Call to action",
      "slug": "call-to-action",
      "agent": null,
      "layer": "slide",
      "matchId": "bd911823-882a-4861-ab71-892924fab125",
      "evidence": "The title/action-title 'Continuing increasing our patent suite to increase protection and exclusivity' implies a call to action to continue expanding the patent suite.",
      "confidence": 0.5
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [
    {
      "to": 29,
      "from": 27,
      "name": "Why Now",
      "slug": "15-why-now",
      "bestFor": "Sales pitches, fundraising, requesting immediate budget approval",
      "matchId": "d5dcfd9b-543a-4162-93c1-7a55c50880a6",
      "evidence": "Rapid Evolution of Platform Sets Stage for Active Q4 and Expanding LNC Intellectual Property Portfolio",
      "position": 1,
      "objective": "Explain why now is the right time for Matinas BioPharma",
      "structure": "The Context (Trends) -> The Trigger Event -> The Window of Opportunity",
      "confidence": 0.6,
      "description": "Create temporal urgency by proving that the window of opportunity is opening or closing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}